33617-58-2

Basic information

• Product Name: 2,4-Dibenzyloxybenzyl Alcohol
• Synonyms: 2,4-Dibenzyloxybenzyl Alcohol;(2,4-Bis-benzyloxy-phenyl)-methanol
• CAS NO: 33617-58-2
• Molecular Formula: C₂₁H₂₀O₃
• Molecular Weight: 320.3817
• Mol File: 33617-58-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2,4-Dibenzyloxybenzyl Alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dibenzyloxybenzyl Alcohol(33617-58-2)
• EPA Substance Registry System: 2,4-Dibenzyloxybenzyl Alcohol(33617-58-2)

Safety Data

• Hazardous Substances Data: 33617-58-2(Hazardous Substances Data)

Usage

General Description

2,4-Dibenzyloxybenzyl alcohol is an organic compound with the chemical formula C21H22O3. It is a white to slightly yellow crystalline powder that is commonly used as a chemical building block in organic synthesis. 2,4-Dibenzyloxybenzyl Alcohol is often utilized in the production of various pharmaceuticals, such as antihistamines and antihypertensive drugs, due to its ability to serve as a protective group for alcohols in organic chemistry reactions. In addition, 2,4-Dibenzyloxybenzyl alcohol is also employed in the manufacturing of fragrances and flavors, as well as in the synthesis of other specialty chemicals. Overall, this chemical plays a crucial role in the development of a wide range of products across different industries.

Upstream product

• 13246-46-3 2,4-dibenzyloxybenzaldehyde 
• 121903-70-6 benzyl 2,4-bis(benzyloxy)benzoate 
• 100-39-0 benzyl bromide 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 100-44-7 benzyl chloride 

Downstream Products

• 113954-22-6 2,4-di(benzyloxy)benzyl chloride 
• 33617-59-3 1,3-dihydroxy-4-dihydroxymethyl benzene 
• 66056-40-4 2-(2,4-bis(benzyloxy)phenyl)acetic acid 
• 113954-23-7 2,4-dibenzyloxyphenylacetonitrile 
• 113954-20-4 (S)-N¹-(5-Amino-pentyl)-2-[2-(2,4-dihydroxy-phenyl)-acetylamino]-succinamide; hydrochloride 
• 113954-14-6 2-[2-(2,4-Bis-benzyloxy-phenyl)-acetylamino]-succinamic acid 4-nitro-phenyl ester 
• 113954-18-0 (S)-N¹-(5-{3-[4-(3-Amino-propylamino)-butylamino]-propionylamino}-pentyl)-2-[2-(2,4-dihydroxy-phenyl)-acetylamino]-succinamide; hydrochloride 
• 113954-15-7 (S)-N¹-(5-Amino-pentyl)-2-[2-(2,4-bis-benzyloxy-phenyl)-acetylamino]-succinamide 

Relevant articles and documents

The total large-scale synthesis of argiopine

The total large-scale synthesis of a natural toxin argiopine, a polymethylenepolyamine derivative, was developed. It consisted of 26 stages and included three key block schemes. Most of the stages proceeded quantitatively, which excluded the necessity of using the chromatographic separation of intermediates.

Selective endothelin A receptor ligands. 1. Discovery and structure-activity of 2,4-disubstituted benzoic acid derivatives

This paper describes the discovery of a new non-peptide endothelin A (ET(A)) selective ligand, 2,4-dibenzyloxybenzoic acid 3, which inhibits the binding of [125I]ET-1 to ET(A) receptors with an IC50 of 9 μM (ET-1 = endothelin-1). Optimisation of 3 resulted in compound 52 which had an IC50 of 1 μM. One of the analogues of 3, compound 15, was examined in a functional assay and shown to antagonise ET-1-induced contraction of rat aorta. The identification of 3 was made through the application of ChemDBS-3D searching of our corporate database. The 3D query, using an aromatic ring to a carboxylic acid group separated by 10.2 ± 1.1 A, was derived from an examination of common pharmacophoric distances found in the low energy conformations of two known ET(A) antagonists, the cyclic pentapeptide BQ 123 1 and myriceron caffeoyl ester 2.

Amide compounds, their production and use

A compound is provided which has the formula STR1 wherein m is an integer of 1 to 3; n is an integer of 1 or 2; p is an integer of 1 or 2; q is an integer of 1 to 6; x is an integer of 2 to 6; Ph is phenylene or a pharmceutically acceptable salt thereof. Also provided is a method for glutamate receptor inhibition which comprises administering to a mammal in need thereof an effective amount of said compound or a pharmaceutically acceptable salt thereof. Compositions for glutamate receptor inhibition are provided which contain an effective amount of said compound to provide a glutamate receptor inhibition effect, together with at least one pharmaceutically acceptable carrier, dilient or excipient therefor.